Newsroom | 4458 results

COLUMBUS, Ohio--(BUSINESS WIRE)--Armatus has published data in Molecular Therapy Nucleic Acids describing TVR110, a first-in-class vectorized microRNA for CMT1A....

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...

SAN DIEGO--(BUSINESS WIRE)--Voro Therapeutics, a biotechnology company pioneering tumor-activated biologics to improve the safety and efficacy of cancer therapies, today announced upcoming oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 and the Antibody Engineering & Therapeutics (AET) Europe conference. Voro Therapeutics will present new preclinical data showcasing the power of its proprietary PrimeBody biologics platform and the broad therapeu...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome FFPE kits that are now shipping to customers. This new solution is a breakthrough that enables true whole transcriptome single cell RNA sequencing from formalin-fixed, paraffin-embedded samples. Beginning today, cancer, neuroscience, and translational researchers can access...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs). Building on the eProtein Discovery™ membrane protein workflow capabilities1, the nanodisc panel allows membrane protein scientists focusing on GPCR research to identify optimal membrane environments and increase production of challenging therapeut...

SAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services, today announced it has entered an international collaboration with Rosebud Biosciences (“Rosebud”), Kantify, and Incite to evaluate off-target chemotherapeutic toxicities in patient-specific organoids. Building on iXCells’ recent partnership with Rosebud1 and funded by Incite, the project will initially focus on predicting toxicity in heart, liver, and kidn...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cellino Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026...

北京--(BUSINESS WIRE)--(美國商業資訊)-- 以創新技術驅動新藥研發的國際性生物科技公司百奧賽圖（北京）醫藥科技股份有限公司（以下簡稱「百奧賽圖」，SSE: 688796；HKEX: 02315）今日宣布與總部位於西雅圖、深耕尖端細胞療法的生物科技公司Moonlight Bio, Inc.達成策略性合作協議。此次合作旨在開發下一代細胞療法，以因應多種極具挑戰性的難治性癌症。 百奧賽圖董事長兼執行長沈月雷博士表示：「我們欣然與尖端細胞療法領域的先鋒Moonlight Bio達成合作。此次策略性合作將利用我們自主研發的現成全人抗體庫，加快針對難治性癌症的創新細胞療法的開發。這同時也展示了百奧賽圖全人抗體發現平台在傳統藥物形式之外的廣泛適用性和平台價值。透過整合雙方優勢，我們可望推動變革性細胞療法的開發進程，為克服耐藥問題、為病患帶來新的治療希望貢獻力量。」 根據協議條款，百奧賽圖將提供針對治療標靶的全人抗體分子，Moonlight Bio將負責相關細胞療法的臨床前開發工作。 關於百奧賽圖 百奧賽圖（股票代號：688796.SH; 02315.HK）是一家以創新技術驅動新藥...

北京--(BUSINESS WIRE)--（ビジネスワイヤ） -- 革新的な技術により新規抗体ベースの医薬品の研究開発を推進するグローバルなバイオテクノロジー企業であるバイオサイトジェン（バイオサイトジェン、SSE：688796；HKEX：02315）は、米シアトルを拠点とし、先進的な細胞療法を業界に先駆けて開発しているバイオテクノロジー企業であるムーンライト・バイオとの戦略的提携を発表しました。この提携の目的は、治療が困難な難治性がんに対する最先端の細胞療法を開発することです。 バイオサイトジェンの社長兼CEOであるシェン・ユエレイは、「先進的な細胞療法において業界をリードするムーンライト・バイオと提携できることを大変嬉しく思います。この戦略的提携は、当社独自の既製ヒト抗体ライブラリーを活用し、治療が困難とされているがんに対する最先端細胞療法の開発を加速させるものです。また、バイオサイトジェンの抗体創薬プラットフォームが、従来の薬剤モダリティを超えた汎用性、さらに幅広い適用性を持つことを示すものです。両社のノウハウを融合することで、薬剤耐性を克服し、治療が最も困難ながんと闘う患者さ...

ZURICH--(BUSINESS WIRE)--CDR-Life, Inc., a clinical-stage biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, today announced achievement of the first preclinical milestone under its 2025 license agreement with Boehringer Ingelheim. This milestone marks continued progress in the companies’ efforts to develop next-generation antibody-based therapies for autoimmune diseases. The candidate is a trispecific M-gager®, an antibody-based T...